跳至主要内容
临床试验/ISRCTN71083772
ISRCTN71083772已完成不适用

A multi-centre, double-blind, randomised, vehicle-controlled study for a quantitative estimation of hair re-growth in male subjects with androgenetic alopecia treated over 6 month with two ethanolic PSK 3841 solutions (2.5% and 5%)

ProStrakan Pharmaceuticals (France)0 个研究点目标入组 120 人开始时间: 2005年10月6日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Men aged between 18 and 50 years with an androgenetic alopecia rated as Norwood-Hamilton stage IIIa, IIIv, IV, IVa and V
  • 2. Subjects in good health, with no relevant abnormalities in their medical history, physical examination and vital signs
  • 3. Willingness to refrain from using any hair enhancement products or procedures for the duration of the study

排除标准

  • 1. Men whose female partner is pregnant or of childbearing potential and not using adequate efficacious contraception
  • 2. Subjects with hair loss due to causes other than androgenetic balding
  • 3. Subjects with scalp diseases other than androgenetic balding
  • 4. Subjects who have had a clinically important illness within the past 6 months before the study entry, which potentially could affect hair growth/loss
  • 5. Any pathology or abnormality of the skin in the areas to be treated

研究者

发起方
ProStrakan Pharmaceuticals (France)

相似试验